Patient-derived xenograft models of BRCA-wildtype and CCNE1-amplified platinum-resistant ovarian cancer, which are associated with increased baseline activation of ATR/CHK1, demonstrated tumor reduction and a significant increase in OS when treated with the combination of PARPi and ATRi (185). This evidence concerns the gene CHEK1 and neoplasm.